Lipoxen awarded PATH funding for malaria study
This article was originally published in Scrip
Executive Summary
Lipoxen has received funding from the PATH Malaria Vaccine Initiative for a feasibility study to test whether its ImuXen technology will enhance the performance of malaria vaccine candidates. The amount was not disclosed.